Indeed, it appears that there are indications of multiple...

Indeed, it appears that there are indications of multiple instances of complete tumor eradication, potentially spanning various cancer types. Notably, there is growing interest from both capital and pharmaceutical investment sectors in the United States after the JP Morgan conferenece. Additionally, it was noted that dose escalation has already occurred in the OASIS trial, although formal announcements regarding this development may not have been widely known. Regarding OBD, they are "zeroing in" and seems to be a focus on its imminent advancement, possibly 3x10^8 or even 10^9???. Furthermore, Azer-cel discussions with the FDA regarding a registration trial seem to be all but a given, was good to see Nick mention the substantial market potential of Azer Cel within the context of blood cancers. Overall great presentation and really liked his direct answers during the Q&A.

*It appears that Imugene has been responsive to investor feedback, as evidenced by the incorporation of Fast Track designation into their presentation slides, reflecting an alignment with investor interests.